Literature DB >> 21295399

Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.

Markus Aly1, Fredrik Wiklund, Jianfeng Xu, William B Isaacs, Martin Eklund, Mauro D'Amato, Jan Adolfsson, Henrik Grönberg.   

Abstract

BACKGROUND: More than 1 million prostate biopsies are conducted yearly in the United States. The low specificity of prostate-specific antigen (PSA) results in diagnostic biopsies in men without prostate cancer (PCa). Additional information, such as genetic markers, could be used to avoid unnecessary biopsies.
OBJECTIVE: To determine whether single nucleotide polymorphisms (SNPs) associated with PCa can be used to determine whether biopsy of the prostate is necessary. DESIGN, SETTINGS, AND PARTICIPANTS: The Stockholm-1 cohort (n = 5241) consisted of men who underwent a prostate biopsy during 2005 to 2007. PSA levels were retrieved from databases and family histories were obtained using a questionnaire. Thirty-five validated SNPs were analysed and converted into a genetic risk score that was implemented in a risk-prediction model. RESULTS AND LIMITATIONS: When comparing the nongenetic model (based on age, PSA, free-to-total PSA, and family history) with the genetic model and using a fixed number of detected PCa cases, it was found that the genetic model required significantly fewer biopsies than the nongenetic model, with 480 biopsies (22.7%) avoided, at a cost of missing a PCa diagnosis in 3% of patients characterised as having an aggressive disease. However, the overall genetic model does not discriminate between aggressive and nonaggressive cases.
CONCLUSION: Although the genetic model reduced the number of biopsies more than the nongenetic model, the clinical significance of this finding requires further evaluation.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21295399      PMCID: PMC4417350          DOI: 10.1016/j.eururo.2011.01.017

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  22 in total

1.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

2.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.

Authors:  Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian L Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

3.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

4.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Authors:  Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon T Bergthorsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C Walsh; Dorine W Swinkels; Sebastian Navarrete; Sarah D Isaacs; Katja K Aben; Theresa Graif; John Cashy; Manuel Ruiz-Echarri; Kathleen E Wiley; Brian K Suarez; J Alfred Witjes; Mike Frigge; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; Lambertus A Kiemeney; William B Isaacs; William J Catalona; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

5.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Thorarinn Blondal; Arnaldur Gylfason; Bjarni A Agnarsson; Kristrun R Benediktsdottir; Droplaug N Magnusdottir; Gudbjorg Orlygsdottir; Margret Jakobsdottir; Simon N Stacey; Asgeir Sigurdsson; Tiina Wahlfors; Teuvo Tammela; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Berta Saez; Javier Godino; Sebastian Navarrete; Fernando Fuertes; Laura Murillo; Eduardo Polo; Katja K Aben; Inge M van Oort; Brian K Suarez; Brian T Helfand; Donghui Kan; Carlo Zanon; Michael L Frigge; Kristleifur Kristjansson; Jeffrey R Gulcher; Gudmundur V Einarsson; Eirikur Jonsson; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Jeffrey R Smith; Johanna Schleutker; Rosa B Barkardottir; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2009-09-20       Impact factor: 38.330

Review 6.  A systematic review and meta-analysis of familial prostate cancer risk.

Authors:  L E Johns; R S Houlston
Journal:  BJU Int       Date:  2003-06       Impact factor: 5.588

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.

Authors:  Jielin Sun; Siqun Lilly Zheng; Fredrik Wiklund; Sarah D Isaacs; Lina D Purcell; Zhengrong Gao; Fang-Chi Hsu; Seong-Tae Kim; Wennuan Liu; Yi Zhu; Pär Stattin; Hans-Olov Adami; Kathleen E Wiley; Latchezar Dimitrov; Jishan Sun; Tao Li; Aubrey R Turner; Tamara S Adams; Jan Adolfsson; Jan-Erik Johansson; James Lowey; Bruce J Trock; Alan W Partin; Patrick C Walsh; Jeffrey M Trent; David Duggan; John Carpten; Bao-Li Chang; Henrik Grönberg; William B Isaacs; Jianfeng Xu
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

9.  Multiple loci identified in a genome-wide association study of prostate cancer.

Authors:  Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

10.  Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?

Authors:  Fredrik Wiklund
Journal:  Genome Med       Date:  2010-07-29       Impact factor: 11.117

View more
  66 in total

1.  The association between rs9642880 gene polymorphism and bladder cancer risk: a meta-analysis.

Authors:  Jingyuan Tang; Xiao Li; Xuping Jiang; Weizhang Xu; Zhen Xu; Wei Wang; Bianjiang Liu; Qiang Lv; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Authors:  Aubrey R Turner; Brian R Lane; Dan Rogers; Isaac Lipkus; Kathryn Weaver; Suzanne C Danhauer; Zheng Zhang; Fang-Chi Hsu; Sabrina L Noyes; Tamara Adams; Helga Toriello; Thomas Monroe; Trudy McKanna; Tracey Young; Ryan Rodarmer; Richard J Kahnoski; Mouafak Tourojman; A Karim Kader; S Lilly Zheng; William Baer; Jianfeng Xu
Journal:  Cancer       Date:  2016-07-19       Impact factor: 6.860

3.  Utility of genome-wide association study findings: prostate cancer as a translational research paradigm.

Authors:  A R Turner; A K Kader; J Xu
Journal:  J Intern Med       Date:  2012-04       Impact factor: 8.989

4.  Prostate cancer: does genetic score justify early prostate biopsy?

Authors:  Toru Sugihara; Michael W Kattan
Journal:  Nat Rev Urol       Date:  2013-10-22       Impact factor: 14.432

Review 5.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

6.  Utility of single nucleotide polymorphisms in prostate biopsy decisions.

Authors:  Stacy Loeb; R Scott Braithwaite; Richard B Hayes
Journal:  Rev Urol       Date:  2012

7.  Prostate cancer: improving PSA testing by adjusting for genetic background.

Authors:  Peter T Scardino
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

Review 8.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

9.  Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Authors:  Haitao Chen; Xu Liu; Charles B Brendler; Donna P Ankerst; Robin J Leach; Phyllis J Goodman; M Scott Lucia; Catherine M Tangen; Li Wang; Fang-Chi Hsu; Jielin Sun; A Karim Kader; William B Isaacs; Brian T Helfand; S Lilly Zheng; Ian M Thompson; Elizabeth A Platz; Jianfeng Xu
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

10.  Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Authors:  Jielin Sun; Rong Na; Fang-Chi Hsu; S Lilly Zheng; Fredrik Wiklund; Lynn D Condreay; Jeffery M Trent; Jianfeng Xu
Journal:  Eur Urol       Date:  2012-12-05       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.